Browsing Tag
Cosette Pharmaceuticals
6 posts
Mayne Pharma secures A$13.3m legal costs award from Cosette as MYX investors weigh takeover fallout
Mayne Pharma wins A$13.27m legal-costs award from Cosette as MYX investors weigh takeover fallout. Read more on the market impact.
How Cosette Pharmaceuticals used CGT exclusivity to unlock a long-ignored ear infection drug market
Cosette Pharmaceuticals secures FDA approval with CGT exclusivity for a long-protected otic drug. Read what this signals for specialty generics.
Can pharma M&A survive Australia’s new national interest doctrine?
Australia’s FIRB blocked Cosette’s $430M takeover of Mayne Pharma. Can foreign pharma buyers still close deals in this new national interest era?
Australia kills Cosette’s Mayne Pharma (ASX: MYX) buyout—citing drug supply risk and sovereignty
Australia blocks Cosette’s $430M bid to acquire Mayne Pharma, citing critical medicine supply risks. Find out what triggered the decision and future implications.
Cosette Pharmaceuticals to acquire Mayne Pharma in $430m deal, strengthening women’s health and dermatology portfolio
Cosette Pharmaceuticals has announced a definitive agreement to acquire Mayne Pharma Group Limited, a move that will significantly…
FDA approves first generic RECTIV ointment by Cosette Pharmaceuticals
In a landmark move for the pharmaceutical industry, Cosette Pharmaceuticals, Inc. has received approval from the U.S. Food…